⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 10, 2024Inflammatory Bowel Diseases

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Yun Qiu Shixian Hu Kang Chao Ling-Jie Huang Zicheng Huang Ren Mao Fengyuan Su Chuhan Zhang Xiaoqing Lin Qian Cao Xiang Gao Minhu Chen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Achieving long-term clinical remission in Crohn's disease (CD) with antitumor necrosis factor α (anti-TNF-α) agents remains challenging.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qiu et al. (2024) studied this question.

synapsesocial.com/papers/68e5cc66b6db64358756292d https://doi.org/10.1093/ibd/izae176

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1P1022Machine learning for predicting secondary non-response of Infliximab treatment in Crohn’s disease:a single-center retrospective studyCohort Study · 2026 · 1 citations
2Development and validation of a machine learning-based predictive model for clinical remission in Crohn’s disease patients receiving Adalimumab therapy2025 · 7 citations
3Development and validation of a novel multimodal deep learning model integrating histopathology, radiology, and clinical data to predict primary non-response to infliximab in patients with crohn’s disease2025 · 4 citations
4Development and Validation of a Machine Learning Model to Predict Anti-Drug Antibody Formation During Infliximab Induction in Crohn’s Disease2025 · 5 citations
5Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn’s diseaseOriginal Research · 2026